Study S002362

Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07820358
Acronym: SWIFT
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 48
Start: 2027-01-01
Primary completion: 2028-12-31
Lead sponsor: The Methodist Hospital Research Institute
Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight
Interventions: DRUG:Semaglutide (Wegovy) weekly injection; DEVICE:LNG-IUD (Progestin); BEHAVIORAL:Structured Weight Loss Program
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Pathological Response Rate [6 months]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005161	Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities. Podder V, Clinical cancer research : an official journal of the American Association for Cancer Research	2026	Nonrandomized study	PMID 41329840 DOI	registry reference BACKGROUND:41329840
R0002951	GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. Dai H, JAMA oncology	2025	Nonrandomized study	PMID 40839273 DOI	registry reference BACKGROUND:40839273
R0006897	Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. Wang L, JAMA network open	2024	Nonrandomized study	PMID 38967919 DOI	registry reference BACKGROUND:38967919
R0017722	Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer. Kong W, Gynecologic oncology	2024	Randomized trial	PMID 39388742 DOI	registry reference BACKGROUND:39388742
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference BACKGROUND:33567185
R0023595	Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway. Zhu XX, Chinese medical journal	2021	Preclinical	PMID 33470656 DOI	registry reference BACKGROUND:33470656